Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

Viatris logo

Viatris

Status

Conditions

Pulmonary Arterial Hypertension

Treatments

Drug: sildenafil (Revatio) 20 mg TID

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT00866983
A1481270

Details and patient eligibility

About

The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit from continued treatment with Sildenafil. It will be supplied until patient gets access to Sildenafil through Brazilian State Health Secretary from where patient resides.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject who completed the A1481244 study and are judged by the Investigator to derive clinical benefit from continuous treatment with Sildenafil 20 mg therapy.
  • Subject who resides in a Brazilian State where Sildenafil is not supplied by State Health Secretary.

Exclusion criteria

  • Pregnant or lactating women.
  • Current participation in other studies and during study participation.

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems